Search News & Insights
Matheson advises on the sale of US biotech firm Dyax to UK-listed Shire
Matheson advised US biotech firm Dyax on Irish tax matters relating to its US$5.9 billion sale to Shire, the UK-listed pharmaceutical company. The acquisition is intended to enhance Shire’s position in treating rare genetic diseases.
The deal is expected to close in the first half of 2016.